OpenScience.ink

1 week ago • Cureus

Diabetes, Body Fat, and Physical Function in Heart Failure with Preserved Pumping: A Review of Recent Treatment ResponsesDiabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response Evidence.

Article

1 week ago • Diabetes, obesity & metabolism

Effectiveness and Safety of Glucagon-Like Peptide-1 Medicines Added to Insulin for Type 1 DiabetesEfficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists as Adjuncts to Insulin Therapy in Type 1 Diabetes Mellitus: An Overlap-Informed Umbrella Review.

Article

1 week ago • Cureus

Heart and Kidney Benefits in Type 2 Diabetes Compared Between Two Diabetes Drug TypesCardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors.

Article

1 week ago • The international journal of lower extremity wounds

Links Between Diabetes Medicines That Target GLP-1 and Foot Problems in Diabetes Using Real-World Data and Genetic AnalysisAssessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian Randomization.

Article

1 week ago • The British journal of cardiology

Using GLP-1 receptor activators in heart disease: guidance for heart doctorsGLP-1 receptor agonists in cardiovascular disease: a guide for cardiologists.

Article

1 week ago • American journal of physiology. Regulatory, integrative and comparative physiology

Intermittent Cold Exposure Raises Energy Use but Does Not Boost Weight Loss from Tirzepatide in Obese MiceIncreased Energy Expenditure through Intermittent Cold Exposure Does Not Enhance Tirzepatide Induced Weight-loss in Obese Mice.

Article

1 week ago • Diabetes, obesity & metabolism

A Twice-Monthly GLP-1 Receptor Activator with Drug-Free Breaks for Better Effectiveness, Receptor Balance, and Gut ToleranceA Biweekly GLP-1R Agonist Designed With Drug-Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability.

Article

1 week ago • Pharmacology & therapeutics

Targeting long-term inflammation caused by cell death to treat fatty liver disease linked to metabolism problemsCell death-induced chronic inflammation as a therapeutic target for metabolic dysfunction-associated steatohepatitis.

Article

1 week ago • Diabetes, obesity & metabolism

Links Between GLP-1 Receptor Drugs and Heart, Kidney, and Liver Health Compared to Other Diabetes Medicines in Type 2 DiabetesAssociation of GLP-1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 Diabetes.

Article

1 week ago • Current medical research and opinion

Gallbladder disease risk with GLP-1 receptor agonists versus DPP-4 inhibitors in type 2 diabetesA retrospective cohort study on the comparative safety of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on the onset of gallbladder disease in type II diabetes.

Article

1 week ago • Diabetes, obesity & metabolism

Safety and How the Body Processes the UBT251 Injection Acting on Metabolism-Related Receptors: A Early-Stage Controlled StudySafety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study.

Article

1 week ago • Clinical therapeutics

Comparing finerenone combined with two or three diabetes medicines in chronic kidney disease linked to type 2 diabetesFinerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort Study.

Article

1 week ago • International journal of cardiology

Tirzepatide linked to heart structure improvement and better heart relaxation in obesity-related heart failure with preserved pumpingAssociation of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study.

Article

2 weeks ago • Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

New Developments in Drugs Targeting Appetite and Metabolism Systems for Treating Obesity and Type 2 DiabetesRecent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes.

Article

2 weeks ago • Nature

Current and Future Treatments for MASHCurrent therapeutic landscape and future treatment perspectives of MASH.

Article

2 weeks ago • Diabetes, obesity & metabolism

Safety concerns and medication risks of GLP-1 therapies for diabetes and obesity from multiple monitoring sourcesPostmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.

Article

2 weeks ago • Science (New York, N.Y.)

Expected and unexpected effects of widely prescribing GLP-1 medicines(Un)intended consequences of mass-prescribing GLP-1s.

Editorial

2 weeks ago • BMJ medicine

Effectiveness and safety of weight-loss drugs based on glucagon-like peptide 1 in adults with overweight or obesity without diabetesComparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

Article

2 weeks ago • Current medical research and opinion

Preventing Type 2 Diabetes in Obese People: From Insulin Resistance to Using Incretin Receptor TreatmentsFrom insulin resistance to incretin receptor agonism in the prevention of type 2 diabetes mellitus in obese individuals.

Article

2 weeks ago • Diabetes, obesity & metabolism

Incretin-Based Treatments for Heart and Metabolic Health: How They Work, Their Effects, and Best Uses for Different Patient TypesIncretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning.

Article

2 weeks ago • Diabetes care

Short-term risk of serious stomach problems with different opioids in patients using diabetes drugsComparative Short-term Risk of Severe Gastrointestinal Events Associated With Opioid Type Among Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists.

Article

2 weeks ago • Clinical & experimental optometry

Use of GLP-1 receptor drugs and sudden non-artery-related vision loss: an example caseGLP-1 receptor agonist exposure and non-arteritic anterior ischaemic optic neuropathy: an illustrative case.

Article

2 weeks ago • The Journal of the American Academy of Orthopaedic Surgeons

Effects and Considerations of Glucagon-like Peptide-1 Receptor Agonists in Joint Replacement SurgeryThe Effect of Glucagon-like Peptide-1 Receptor Agonists in Total Joint Arthroplasty: Implications, Complications, and Considerations.

Article

2 weeks ago • Diabetes, obesity & metabolism

Combining a Virtual GLP-1 Program and Exercise Support to Improve Body Composition During GLP-1 Weight LossQuality Plus Quantity: Evaluation of a Virtual GLP-1 Programme With Physical Activity Support to Promote Healthy Body Composition Change During GLP-1 Weight Loss.

Article

2 weeks ago • Cureus

Comparing Incretin-Based Treatments and Weight-Loss Surgery for Obesity and Type 2 Diabetes: Effects on Blood Sugar, Heart, Liver, Weight, and Quality of LifeIncretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes.

Article

2 weeks ago • The American journal of gastroenterology

Do Patients Taking GLP-1 Medicines Need Longer Fasting Before Liver Stiffness Scans?Do Patients on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Require Longer Fasting Prior to Vibration Controlled Transient Elastography?

Article

2 weeks ago • Cureus

Multiple Body System Benefits of Low-Dose GLP-1 TreatmentMultisystem Benefits of GLP-1 Microdosing: A Narrative Review.

Article

2 weeks ago • Cureus

Links Between Semaglutide, a Glucagon-Like Peptide-1 Drug, and Irregular Heartbeats: A Review of Overlapping StudiesGlucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses.

Article

2 weeks ago • Cardiovascular diabetology. Endocrinology reports

Which types of heart failure may benefit from GLP-1 receptor agonists?Which heart failure phenotypes benefit from GLP-1 receptor agonists?

Letter

3 weeks ago • Biochemical pharmacology

Challenges in Developing Drugs for Diabetic Kidney Disease: Problems with Testing Targets and Ways to Improve TrialsDrug failure in diabetic kidney disease: translational barriers, target validation and trial de-risking strategies.

Article

← prevpage 13 of 14next →

GLP-1 Therapies Research Papers